Onychomycosis Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) February 14, 2015 -- The report “Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) is a fungal illness of the nails. It is the most common nail disease in adults. It is spread through direct contact with the yeast. Onychomycosis is caused by thickened nail, ragged nail, unsightly nail and pain in the nail. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/onychomycosis-tinea-unguium-pipeline-review-h1-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Companies discussed in this Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2015 report include Actavis plc, Anacor Pharmaceuticals, Inc., Eisai Co., Ltd., Evolva SA, Helix BioMedix, Inc., Mayne Pharma Group Limited, Meiji Seika Pharma Co., Ltd., Moberg Pharma AB, NAL Pharmaceuticals Ltd., Nihon Nohyaku Co., Ltd., Novabiotics Ltd, Nuvo Research Inc., Viamet Pharmaceuticals, Inc.
Signs and symptoms of Onychomycosis may include complaints about the appearance of the nail, meddling with standing walking and exercising, pain, discomfort and inhibited social interaction. Drugs profile discussed in this report include albaconazole, AN-2718, E-1224, ELS-160, EV-086, HB-1275, itraconazole, luliconazole, ME-1111, NAL-3216, NP-213, Small Molecules for Fungal Infections, terbinafine, terbinafine, VT-1161. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269575 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this “Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2015” report include: Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis; Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014; Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015; May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015; Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis; Jun 21, 2012: Mayne Pharma Receives MHRA Approval For Subacap; Mar 30, 2012: Palau Pharma Reports Positive Phase IIb Clinical Results Of Albaconazole For Treatment Of Onychomycosis At American Academy Of Dermatology Annual Meeting; Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin; Feb 09, 2012: Moberg Derma Provides Update On Phase II Study Of MOB-015; Dec 15, 2011: Mayne Pharma Provides Update On Subacap European Marketing Approval Application.
Table of content
List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2015
Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Actavis plc, H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Evolva SA, H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Mayne Pharma Group Limited, H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Nuvo Research Inc., H1 2015
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Onychomycosis (Tinea Unguium) Therapeutics - Recent Pipeline Updates, H1 2015
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2015
Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..2), H1 2015
Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2015
Explore more reports on Infectious Diseases Therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Ritesh Tiwari, Rnrmarketresearch.com, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article